ImmuPharma PLCLSE ImmuPharma Stock Report

ImmuPharma Plc engages in the research, development, and commercialization of pharmaceutical products. The company is focused on the development of drugs based on peptide therapeutics, to treat serious medical conditions such as autoimmune disease. Its portfolio consists of four peptide therapy areas, which include autoimmunity and anti-infectives. Its lead program, Lupuzor is a first-in class autophagy immunomodulator, which is in Phase III for the treatment of Lupus, a life threatening auto immune-disease. Lupuzor has a mechanism of action that does not suppress the immune system and which normalizes the over-activity of CD4 T-cells which are involved in the cell-mediated immune response which leads to the lupus disease. Its core program includes BioAMB and BioCin. BioAMB, a peptide-based drug that offers an improvement on the limiting side effects of Amphotericin-B (AMB) formulations. BioCin is a peptide-based drug based on antibacterial used in high medical need cases.